Abstract | BACKGROUND/AIMS: METHODS: RESULTS: A significantly smaller decrease in hemoglobin concentration was observed in group B compared to group A at every time point. Moreover, the prescribed dose intensity of ribavirin in group B was higher than that of group A, resulting in a higher ratio of sustained virological response (SVR) 24 in group B compared with group A. The physical function of patients in group B was also significantly improved compared to group A at the end of antiviral treatment. CONCLUSION:
L-carnitine supplementation alleviates ribavirin-induced hemolytic anemia in patients with HCV and helps relieve the physical burden of treatment with ribavirin-containing regimens. These advantages significantly increase the likelihood of achieving SVR.
|
Authors | Shinya Sato, Kei Moriya, Masanori Furukawa, Soichiro Saikawa, Tadashi Namisaki, Mitsuteru Kitade, Hideto Kawaratani, Kosuke Kaji, Hiroaki Takaya, Naotaka Shimozato, Yasuhiko Sawada, Kenichiro Seki, Koh Kitagawa, Takemi Akahane, Akira Mitoro, Yasushi Okura, Junichi Yamao, Hitoshi Yoshiji |
Journal | Clinical and molecular hepatology
(Clin Mol Hepatol)
Vol. 25
Issue 1
Pg. 65-73
(03 2019)
ISSN: 2287-285X [Electronic] Korea (South) |
PMID | 30798587
(Publication Type: Journal Article)
|
Chemical References |
- Ribavirin
- Carnitine
- Sofosbuvir
|
Topics |
- Aged
- Anemia, Hemolytic
(diagnosis, etiology)
- Carnitine
(therapeutic use)
- Drug Therapy, Combination
- Female
- Hepatitis C
(drug therapy)
- Humans
- Male
- Middle Aged
- Quality of Life
- Ribavirin
(adverse effects, therapeutic use)
- Sofosbuvir
(therapeutic use)
- Surveys and Questionnaires
- Treatment Outcome
|